US Patent

US8900638 — Solid preparation comprising alogliptin and metformin hydrochloride

Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2029-05-24 · 3y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid preparation containing alogliptin and metformin hydrochloride, useful as a therapeutic drug for diabetes.

USPTO Abstract

The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part and a second part: a first part: a part containing compound (I) or a salt thereof and substantially free of metformin hydrochloride a second part: a part containing metformin hydrochloride and substantially free of compound (I) and a salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US8900638
Jurisdiction
US
Classification
Formulation
Expires
2029-05-24
Drug substance claim
No
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.